#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
proLékaře.cz / Topic

Chronic Heart Failure and Lipidology

We recommend dyslipidémie

Inclisiran −⁠ a new addition to the arsenal of dyslipidemia treatment

23. 12. 2022 Source: Chronic Heart Failure and Lipidology

At the XXIX Congress of the Czech Society of Internal Medicine ČLS JEP, held November 6−9, 2022 in Prague, lectures on innovative dyslipidemia therapy using the small interfering RNA molecule −⁠ inclisiran were presented at the Novartis company symposium.

LDL cholesterol

Use of Inclisiran in a Patient in Secondary Cardiovascular Prevention

Lowering LDL cholesterol (LDL-c) is one of the primary goals for reducing cardiovascular (CV) risk…
23. 12. 2022 Source: Chronic Heart Failure and Lipidology
Kardiolog a pacient

Practical Experiences Using ZULP in Cardiology

The application of a product containing ferric carboxymaltose (FCM) or the use of a contrast agent…
12. 12. 2022 Source: Chronic Heart Failure and Lipidology
Articles on this topic
dyslipidémie

How Will the New Player in Dyslipidemia Therapy Change the "Rules of the Game"?

Inclisiran, as an innovative drug indicated for adult patients with primary hypercholesterolem…
12. 12. 2022 Source: Chronic Heart Failure and Lipidology
levá srdeční komora

Impact of Initial RAAS Inhibitor on Hospitalization Risk in HFrEF Patients

Inhibition of the renin-angiotensin-aldosterone system (RAAS) is considered a key step in the…
23. 11. 2022 Source: Chronic Heart Failure and Lipidology
Nemocnice_lékař_sestra

ESC 2022: Can Modern Treatment of Acute Heart Failure Improve (Re)hospitalization Prevention?

Heart failure (HF) and the possibilities of its therapy were one of the frequently discussed…
19. 10. 2022 Source: Chronic Heart Failure and Lipidology
EKG srdce srdeční selhání

Pharmacotherapy of Chronic Heart Failure with Reduced EF LV -⁠ Latest ESC Recommendations

The European Society of Cardiology (ESC) issued an update in 2021 for the diagnosis and…
22. 11. 2021 Source: Chronic Heart Failure and Lipidology
srdce cevy cholesterol krev ateroskleroza

Ivabradine and/or Sacubitril/Valsartan in the Treatment of Heart Failure with Reduced Ejection Fraction

Ivabradine and sacubitril/valsartan are used in the second line of therapy for heart failure…
7. 9. 2021 Source: Chronic Heart Failure and Lipidology
LDL cholesterol

INFOGRAPHIC: LDL Cholesterol -⁠ Recommended Target Values

Elevated levels of LDL cholesterol are a significant risk factor for cardiovascular diseases, which...
11. 6. 2021 Source: Chronic Heart Failure and Lipidology
LDL cholesterol_kniha

Reduction of LDL Cholesterol in the Prevention of Cardiovascular Morbidity and Mortality –⁠ Results of a Large Meta-Analysis

Elevated LDL cholesterol (LDL-c) is one of the main causes of atherosclerosis. The…
11. 6. 2021 Source: Chronic Heart Failure and Lipidology
PL_glukometr_diabetes

Does Sacubitril/Valsartan Prevent Myocardial Remodeling in Heart Failure Patients with Type 2 Diabetes?

The PROVE-HF study demonstrated reverse myocardial remodeling in patients with chronic heart…
20. 5. 2021 Source: Chronic Heart Failure and Lipidology
Tlakoměr_nizký krevní tlak_hypotenze

INFOGRAPHIC: Prevention and Management of Hypotension During Sacubitril/Valsartan Treatment

Despite the undeniable benefits of sacubitril/valsartan in terms of morbidity and mortality in…
20. 5. 2021 Source: Chronic Heart Failure and Lipidology
medicína_krev_krevní_tlak_měření_doktor_nemocnice

Hypotension during treatment with sacubitril/valsartan: practical tips for prevention and management

Despite the undeniable benefits of sacubitril/valsartan in terms of morbidity and mortality in…
27. 11. 2020 Source: Chronic Heart Failure and Lipidology
Srdeční komora

How to Achieve Left Ventricular Reverse Remodeling and Improve Outcomes in Heart Failure? Summary from HFA ESC Webinar

The current treatment algorithm for chronic heart failure with reduced ejection fraction…
16. 9. 2020 Source: Chronic Heart Failure and Lipidology
Anatomie lidského srdce

Impact of Sacubitril/Valsartan Treatment on Left Ventricular Reverse Remodeling

A meta-analysis evaluated the effect of sacubitril/valsartan on echocardiographic parameters…
1. 6. 2020 Source: Chronic Heart Failure and Lipidology

Treatment of HFrEF with Sacubitril/Valsartan Does Not Have to Be the ‘Last Resort’

The TRANSITION study has provided evidence on the safety and efficacy of administering…
9. 3. 2020 Source: Chronic Heart Failure and Lipidology

Initiation of Sacubitril/Valsartan After Acute Decompensation of Chronic Heart Failure: The Sooner, the Better

The recently published analysis of data from the extended open-label follow-up of participants…
27. 2. 2020 Source: Chronic Heart Failure and Lipidology
srdce_infografika_selhani_kardiologie

Less Ventricular Arrhythmias and ICD Shocks After Introduction of Sacubitril/Valsartan

Is the decrease in the incidence of sudden cardiac death among patients using…
8. 1. 2020 Source: Chronic Heart Failure and Lipidology
1 2
Subscribe
Most read on this topic
Journal on this topic
Issue 7–8
Journal of Czech Physicians
Issue S3 - 29. kongres o ateroskleróze 4.–6. prosince 2025, Olomouc
Athero Review
Issue 4
Transfusion and Haematology Today
Related topic
Interesting links
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#